OakChart

Allarity Therapeutics Inc

ALLRHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.9353+0.0251 (2.76%)
2026-11-11 23:25 CET
Market cap
14.48 USD m
Revenue, TTM
0.34 USD m
Net income, TTM
-12.33 USD m
Free cash flow, TTM
-13.78 USD m
EPS diluted, TTM
-0.79
P/E
-
Compare

Price

ALLR against its 20, 50 and 200-day averages
2050200earnings
0.751.001.251.501.75286K572KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALLRclose 0.9420-day 0.9350-day 1.03200-day 1.210.9452w high52w low

49.2% under the 52-week high of 1.84 on 27 May 2026. 52-week low 0.77 on 3 Feb 2026. Last 15 sessions, 43.0% high to low

Volume 0.82× normal · the line is the 50-bar volume average

Profile

ALLR
52-week range, 15% of the way up
0.771.84

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The company is focused on development of stenoparib, a novel PARP and tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity Therapeutics was founded by Steen Knudsen and Thomas H. Jensen in 2004 and is headquartered in Tarpon Springs, FL.

Employees8
IPODec 21, 2021
Beta0.53
ATR, 14d0.08
Rel volume0.82
Short float1.53%
Insider own5.35%
Inst own8.27%

Snapshot

6 groups

Valuation

Index-
Market Cap14.88M
Enterprise Value10.19M
Income-12.33M
Sales0.34M
Book/sh0.22
Cash/sh1.70
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPODec 21, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S43.76
P/B4.21
P/C0.55
P/FCF-
EV/EBITDA-
EV/Sales29.97
Quick Ratio1.11
Current Ratio1.11
Debt/Eq6.30
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.79
EPS next Y-0.86
EPS next Q-0.21
EPS this Y-2.56%
EPS next Y-7.50%
EPS next 5Y-
EPS past 3/5Y99.25% 94.60%
Sales past 3/5Y- -
EPS Y/Y TTM91.38%
Sales Y/Y TTM-
EPS Q/Q-43.34%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.16.00% -

Ownership

Insider Own5.35%
Insider Trans0.00%
Inst Own8.27%
Inst Trans2.43%
ROA-46.26%
ROE-157.09%
ROIC-348.81%
Gross Margin100.00%
Oper. Margin-3128.99%
Profit Margin-3575.07%
SMA200.95%
SMA50-9.42%
SMA200-22.70%
Trades-

Technical

Shs Outstand15.91M
Shs Float15.06M
Short Float1.53%
Short Ratio1.95
Short Interest0.23M
52W High1.84 -49.15%
52W Low0.77 21.67%
Volatility9.17% 9.13%
ATR (14)0.08
RSI (14)47.00
Beta0.53
Rel Volume0.82
Avg Volume118.21K
Volume97,144

Performance

Perf Week-13.40%
Perf Month7.52%
Perf Quarter-31.23%
Perf Half Y-39.27%
Perf YTD-13.40%
Perf Year-23.34%
Perf 3Y-99.67%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price11.00
Prev Close0.91
Price0.94
Change %2.76%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Jul 28, 2025InitiatedAAscendiant Capital MarketsBuy$9+862.3%

Peers

Mkt cap
TickerCompanyMkt cap
ACRVAcrivon Therapeutics Inc67.28M
APREAprea Therapeutics Inc6.30M
ZNTLZentalis Pharmaceuticals Inc185.72M
LTRNLantern Pharma Inc7.19M
VSTMVerastem Inc1.15B
CRDFCardiff Oncology Inc59.54M
TPSTTempest Therapeutics Inc7.94M
ACTUActuate Therapeutics Inc16.63M
MBRXMoleculin Biotech Inc8.50M
PRLDPrelude Therapeutics Inc301.66M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue (GlobeNewswire)
  • Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor to Drive Stenoparib's Clinical Development (GlobeNewswire) +8.80%
  • Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research (GlobeNewswire) -5.98%
  • Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP Companion Diagnostic, Further Strengthening Stenoparib Development (GlobeNewswire) -5.13%
  • Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement (GlobeNewswire)
  • Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign (GlobeNewswire)
  • Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP Testing for FDA Registration (GlobeNewswire) -5.83%
  • Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP Companion Diagnostic (GlobeNewswire)
  • Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 (GlobeNewswire) +6.72%
  • Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers (GlobeNewswire) -10.60% +5.93%
  • Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm (GlobeNewswire)
  • Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign (GlobeNewswire) +12.00%
  • Allarity Therapeutics Announces that the Stenoparib DRP Test Has Received a Notice of Allowance from the US Patent and Trademark Office (GlobeNewswire)
  • Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer (GlobeNewswire) +10.40%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.210-0.250117,1980.000.001
2026Q12026-05-15-0.170-0.220-0.1720.030.001
2025Q42026-03-31-0.190-0.220-0.2100.320.001
2025Q32025-11-14-0.190-0.230-0.1900.000.001
2025Q22025-08-15-0.150-0.210-0.1490.000.001
2025Q12025-05-09-0.250--0.2450.00--
2024Q32024-11-14-7.710--7.712---
2024Q12024-05-14-664.2-52.800-696.830.000.001
2023Q42024-03-08117,198-150-175.51-0.001
2023Q32023-11-14-1,344-4,903-1,346-0.001
2023Q22023-10-10-6,711-6,711-15,7660.000.001
2023Q12023-07-07-106,236--106,2380.00-1
2022Q42023-05-15-9,552-9,552-192,763-0.001
2022Q32022-11-15-16,320-6,000-568,6880.000.001
2022Q22022-08-22-312-252-603,674-0.001
2022Q12022-05-30-336-396-471,467-0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-100,560--3,520,1040.00-
2022FY-46,404-46,404-1,856,0560.000.00
2023FY-6,156-123,498-6,1530.000.00
2024FY-15.650--15.7910.00-
2025FY-0.780-0.790-6,1563200.00
2026FY--0.800--0.03
2027FY--0.860--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-141000.000.000.00
2026Q3S2026-05-181000.000.000.00
2026Q3S2026-04-081000.000.000.00
2026Q3S2025-11-141000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00
2026Q3S2025-11-021000.000.000.00

Estimate history

EPS, annual-189613.2-1698639.601-3520104.001-1856055.601-6153.264-15.791-0.781-0.7863
Period2019202020212022202320242025TTM
EPS, quarterly-3.405-7.712-1.021-0.245-0.149-0.19-0.21-0.172-0.214
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.12000000.320.34
Period2019202020212022202320242025TTM
Sales, quarterly0000000.320.0250
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual00000.017.30316.08115.911
Period2019202020212022202320242025MRQ
Shares, quarterly1.1682.7597.30317.02214.6216.11116.08115.81915.911
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.340.320.000.000.000.000.000.12
Cost of Goods Sold Incl. D&A0.02-0.010.010.040.120.110.09-
Gross Profit0.340.33-0.01-0.04-0.12-0.11-0.09-
Selling, General and Administrative Excl. Other11.1213.8418.3317.8916.7726.458.2310.15
Research and Development5.527.506.907.876.8714.094.226.37
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.79-13.51-18.34-17.93-16.89-26.56-8.32-10.12
Interest Expense1.060.180.650.500.220.500.323.31
Unusual Expense0.13-0.007.03-5.650.45-1.47-1.455.63
Net Income Before Taxes-12.33-12.13-25.70-12.62-17.58-26.52-6.42-18.98
Income Taxes0.00-0.90-1.18-0.72-1.520.130.20-4.58
Consolidated Net Income-12.33-11.23-24.52-11.90-16.06-26.65-6.62-14.40
Net Income From Continuing Operations-12.33-11.23-24.52-11.90-16.06-26.65-6.60-14.31
Net Income-12.33-11.23-25.38-20.42-21.05-26.65-6.60-14.31
EPS (Recurring)-0.77-0.78-12.73-7,346.12-1,828,528.29-3,656,219.51-1,959,789.02-137,358.78
EPS (Basic, Before Extraordinaries)-0.79-0.78-15.79-6,153.26-1,856,055.60-3,520,104.00-1,698,639.60-189,613.20
EPS (Diluted)-0.79-0.78-15.79-6,153.26-1,856,055.60-3,520,104.00-1,698,639.60-189,613.20
EBITDA-10.82-13.52-18.33-17.89-16.77-26.45-8.23-10.03
Non-Operating Income (Expense)-0.351.560.320.15-0.02-0.930.770.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.430.380.060.061.384.650.450.24
Price To Sales Ratio59.4948.53------
Gross Margin100.00104.06------
Operating Margin-3,128.99-4,220.31------8,430.83
Net Margin-3,575.07-3,509.69------11,927.50
Shares Outstanding15.9116.087.300.010.000.000.000.00
Market Capitalization14.4814.485.192.313.0183.9984.63-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.030.320.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.03-0.030.010.000.010.010.000.01
Gross Profit-0.030.050.310.00-0.01-0.01-0.00-0.01
Selling, General and Administrative Excl. Other2.642.743.232.524.123.027.322.60
Research and Development1.341.301.671.202.321.401.851.02
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.67-2.69-2.92-2.52-4.13-3.04-7.32-2.61
Interest Expense0.720.230.060.060.010.060.070.05
Unusual Expense0.130.000.000.000.00-0.00-0.009.69
Net Income Before Taxes-3.40-2.75-3.37-2.81-2.32-2.73-7.45-11.97
Income Taxes0.000.000.000.000.000.000.00-0.38
Consolidated Net Income-3.40-2.75-3.37-2.81-2.32-2.73-7.45-11.59
Net Income From Continuing Operations-3.40-2.75-3.37-2.81-2.32-2.73-7.45-11.59
Net Income-3.40-2.75-3.37-2.81-2.32-2.73-7.45-12.15
EPS (Recurring)-0.21-0.17-0.21-0.19-0.15-0.25-1.02-3.41
EPS (Basic, Before Extraordinaries)-0.21-0.17-0.21-0.19-0.15-0.25-1.02-7.71
EPS (Diluted)-0.21-0.17-0.21-0.19-0.15-0.25-1.02-7.71
EBITDA-2.64-2.71-2.91-2.56-4.12-3.02-7.32-2.60
Non-Operating Income (Expense)0.110.17-0.40-0.231.820.36-0.060.38
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.190.16-0.050.130.160.140.050.01
Price To Sales Ratio59.4950.4554.27-----
Gross Margin-204.0097.50-----
Operating Margin--10,752.00-911.88-----
Net Margin--11,000.00-1,054.06-----
Shares Outstanding15.9115.8216.0816.1114.6217.027.302.76
Market Capitalization14.4817.5317.0723.1015.234.155.192.98

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments14.6919.530.172.0319.550.301.52
Short Term Receivables0.902.230.950.871.341.121.66
Inventories0.000.000.000.000.000.000.00
Other Current Assets2.350.580.862.070.150.290.16
Total Current Assets17.9322.341.974.9721.051.723.34
Net Property, Plant & Equipment0.330.310.020.030.090.350.44
Total Investments and Advances0.000.000.000.000.350.840.14
Intangible Assets0.000.009.879.5528.1430.4927.69
Other Assets0.000.000.000.000.000.000.00
Total Assets18.2622.6511.8614.5449.6333.4031.61
Short Term Debt Incl. Current Port. of LT Debt1.401.351.302.650.101.520.62
Accounts Payable4.284.188.426.250.000.000.00
Income Tax Payable0.080.070.060.040.060.060.04
Other Current Liabilities2.675.234.392.2820.563.964.05
Total Current Liabilities8.4310.8414.1711.2220.725.534.72
Long Term Debt0.000.000.001.080.991.150.34
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities--0.450.351.962.131.85
Other Liabilities0.000.000.000.007.180.153.79
Total Liabilities8.4310.8414.6112.6530.858.9610.70
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.001.742.000.630.000.00
Common Equity9.8311.81-4.49-0.1118.1524.4418.09
Total Shareholders Equity9.8311.81-2.751.8918.7824.4418.09
Accumulated Minority Interest0.000.000.000.000.000.002.82
Total Equity9.8311.81-2.751.8918.7824.4420.90
Total Liabilities & Stockholders Equity18.2622.6511.8614.5449.6333.4031.61
Book Value Per Share0.611.62-457.93-5,970.621,883,356.434,828,000.62125,214.86
Tangible Book Value Per Share0.611.62-1,463.99-510,514.48-1,035,783.78-1,195,591.46-66,480.80
Full-Time Employees876913--
Price to Book Ratio4.100.25-0.452.084.632.85-
Return on Assets-54.91-142.07-90.14-50.04-64.18-20.31-
Return on Equity-103.80-541.17--155.34-116.79-31.05-
Return on Invested Capital-114.28-207.56--540.13-134.78-25.80-77.67
Quick Ratio2.132.060.140.441.020.310.71
Current Ratio2.132.060.140.441.020.310.71

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-12.33-11.23-24.52-11.90-16.06-26.65-6.62-14.40
Depreciation-0.03-0.010.010.040.060.110.090.09
Other Funds (Non Cash)3.132.107.54-4.331.125.90-1.335.90
Funds from Operations-9.23-9.14-17.41-16.10-16.49-20.62-7.70-12.17
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-4.48-5.680.063.35-0.335.570.452.06
Income Taxes Payable0.000.010.010.02-0.020.010.030.50
Cash from Operating Activities-13.71-14.82-17.35-12.74-16.82-15.05-7.25-10.11
Capital Expenditures-0.07-0.01-0.300.00-0.020.00-0.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.24
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.24
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.811.000.000.00
Cash from Investing Activities-0.07-0.01-0.300.000.791.00-0.000.23
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock1.8110.6536.7913.640.0032.853.489.13
Repurchase of Common Pref Stock-0.89-3.19-3.50-6.650.000.000.000.00
Sale of Common Pref Stock2.7013.8440.2920.300.0032.853.489.13
Proceedsfrom Stock Options2.7013.8440.291.160.0030.083.489.13
Issuance or Reduction of Debt, Net20.000.000.00-2.651.000.972.553.55
Change in Long Term Debt0.000.000.00-2.651.000.000.000.00
Issuance of Long Term Debt0.000.000.001.051.000.000.000.00
Reduction of Long Term Debt0.000.000.00-3.700.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-2.310.000.00-1.48
Other Financing Activities Uses0.000.000.000.00-2.310.000.00-1.48
Cash from Financing Activities21.8110.6536.7910.99-1.3133.826.0311.20
Exchange Rate Effect1.15-0.670.23-0.11-0.19-0.51-0.01-0.03
Net Change in Cash9.18-4.8519.37-1.86-17.5319.26-1.231.29
Free Cash Flow-13.78-14.83-17.65-12.74-16.84-15.05-7.25-10.12
Preferred Dividends (Cash Flow)-0.00----0.000.00
Deferred Taxes & Investment Tax Credit-0.00-0.450.10-1.610.020.17-3.76

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments26.9829.8114.6916.8917.8027.70
Short Term Receivables1.311.080.901.661.611.11
Inventories0.000.000.000.000.000.00
Other Current Assets3.443.612.351.911.470.60
Total Current Assets31.7334.5017.9320.4720.8829.42
Net Property, Plant & Equipment0.390.420.330.330.320.31
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets32.1234.9218.2620.8021.2029.73
Short Term Debt Incl. Current Port. of LT Debt22.2921.501.401.391.381.36
Accounts Payable4.114.244.284.604.614.35
Income Tax Payable0.080.080.080.080.080.08
Other Current Liabilities2.102.192.672.712.985.28
Total Current Liabilities28.5828.008.438.799.0411.06
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities28.5828.008.438.799.0411.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3.546.929.8312.0112.1718.67
Total Shareholders Equity3.546.929.8312.0112.1718.67
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3.546.929.8312.0112.1718.67
Total Liabilities & Stockholders Equity32.1234.9218.2620.8021.2029.73
Book Value Per Share0.220.440.610.750.831.10
Tangible Book Value Per Share0.220.440.610.750.831.10
Full-Time Employees--8---
Price to Book Ratio4.101.781.451.900.920.58
Return on Assets-46.26-34.80-54.91-74.37-92.52-112.25
Return on Equity-157.09-87.92-103.80-122.61-150.58-383.74
Return on Invested Capital-96.30-39.74-34.32-23.36-19.07-14.63
Quick Ratio1.111.232.132.332.312.66
Current Ratio1.111.232.132.332.312.66

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.40-2.75-3.37-2.81-2.32-2.73
Depreciation0.03-0.030.01-0.040.010.01
Other Funds (Non Cash)1.210.261.420.260.250.18
Funds from Operations-2.17-2.52-1.95-2.59-2.06-2.54
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.40-1.97-1.29-0.82-3.42-0.15
Income Taxes Payable0.000.000.000.000.010.00
Cash from Operating Activities-2.56-4.49-3.24-3.41-5.48-2.69
Capital Expenditures0.00-0.06-0.010.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.06-0.010.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.00-0.26-0.242.31-2.5611.14
Repurchase of Common Pref Stock0.00-0.26-0.48-0.14-2.560.00
Sale of Common Pref Stock0.000.000.242.450.0011.14
Proceedsfrom Stock Options0.000.000.242.450.0011.14
Issuance or Reduction of Debt, Net0.0020.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.0019.74-0.242.31-2.5611.14
Exchange Rate Effect-0.27-0.061.280.19-1.86-0.29
Net Change in Cash-2.8315.12-2.21-0.91-9.908.17
Free Cash Flow-2.56-4.56-3.25-3.41-5.48-2.69

Revenue breakdown

Pharmaceutical Preparations2025: 320.00K
United States2025: 320.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.53%0.2M15.1M111.10K
2026-10-151.12%0.2M15.1M99.95K
2026-09-300.79%0.1M15.1M102.44K
2026-09-150.74%0.1M15.1M102.57K
2026-08-310.79%0.1M15.1M115.34K
2026-08-140.71%0.1M15.1M149.91K
2026-07-310.80%0.1M15.0M181.98K
2026-07-150.97%0.1M15.0M197.46K
2026-06-300.54%0.1M15.0M193.82K
2026-06-151.17%0.2M15.0M187.96K
2026-05-291.17%0.2M15.0M199.32K
2026-05-151.98%0.3M15.0M179.01K
2026-04-301.85%0.3M14.8M170.05K
2026-04-151.99%0.3M15.0M169.88K
2026-03-312.41%0.4M14.7M168.56K
2026-03-131.94%0.3M14.9M178.63K
2026-02-271.53%0.2M14.9M161.95K
2026-02-131.92%0.3M14.9M167.89K
2026-01-301.45%0.2M14.9M165.81K
2026-01-151.70%0.3M14.9M189.57K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-028-KCurrent report2026-10-28SEC
2026-10-30424B5SEC
2026-10-308-KCurrent report2026-10-28SEC
2026-10-094Statement of changes in beneficial ownership of securities2026-01-22SEC
2026-10-018-KCurrent report2026-09-30SEC
2026-09-298-KCurrent report2026-09-28SEC
2026-09-168-KCurrent report2026-09-15SEC
2026-09-148-KCurrent report2026-09-11SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-07-018-KCurrent report2026-06-26SEC
2026-06-228-KCurrent report2026-06-18SEC
2026-06-028-KCurrent report2026-05-27SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-01-28SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-01-28SEC
2026-05-113Initial statement of beneficial ownership of securities2025-06-10SEC
2026-05-088-KCurrent report2026-05-08SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-01-28SEC
2026-05-068-KCurrent report2026-05-05SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-26SEC
2026-04-304/A2026-01-28SEC
2026-04-304Statement of changes in beneficial ownership of securities2026-01-28SEC
2026-04-288-KCurrent report2026-04-27SEC
2026-04-27424B3SEC
2026-04-24EFFECTEffectiveness filing by commission orderSEC
2026-04-24S-3/ASEC
2026-04-22CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RENAISSANCE TECHNOLOGIES LLC2.08%
VANGUARD CAPITAL MANAGEMENT LLC1.08%
GEODE CAPITAL MANAGEMENT, LLC0.98%
STATE STREET CORP0.86%
Militia Capital Management LLC0.62%
CITADEL ADVISORS LLC0.58%
VANGUARD FIDUCIARY TRUST CO0.47%
HRT FINANCIAL LP0.23%
NORTHERN TRUST CORP0.23%
JANE STREET GROUP, LLC0.23%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.08%
Fidelity Extended Market Index Fund0.52%
Fidelity Total Market Index Fund0.14%
Fidelity Series Total Market Index Fund0.14%

OakChart. ALLR. Cached 15 minutes.

Some panels did not load: insider.